期刊文献+

2型神经纤维瘤病患者临床各因素与预后相关性分析 被引量:11

Analysis clinical predictors of the risk of mortality in patients with neurofibromatosis type 2
原文传递
导出
摘要 目的分析2型神经纤维瘤病(NF2)的临床特征,明确临床各因素与预后存在的相关性。方法回顾性分析了175例临床确诊为NF2患者的临床资料、影像学表现及预后。男92例,女83例,家族遗传性患者27例,散发患者148例,平均年龄29:5岁;随访期为1-255个月,生存154例,死亡21例,中位生存时间为(208.4±10.6)个月(95%CI,187.6-229.1)。Kaptan-Meier生存分析法分析各因素对生存时间的影响。结果患者首次出现症状年龄≤19岁和〉19岁的两组的生存率存在明显差异(P=0.006),有或无脊髓肿瘤的生存率存在明显差异(P=0.009);Cox回归模型分析结果伴随脊髓肿瘤为NF2患者预后的影响因素(P=0.048)。结论NF2临床表型多样且不同个体之间差异大,伴随脊髓肿瘤是患者预后不佳的重要因素。 Objective To analyse clinical characteristics of neurofibromatosis type 2 (NF2) and evaluate clinical predictors of the risk of mortality in patients of NF2. Methods A total of 175 cases of NF2 patients, confirmed with Manchester criteria for clinical diagnosis of NF2, were retrospectively studied for the clinical manifestations and imaging. Average age of this group was 29. 5 year-old, including 92 males and 83 females. 27 cases were inherited cases and 148 were sporadic cases. During the follow-up from 1 - 255 months, 154 NF2 cases still survive while 21 cases died. The median survival time was 208.4 ± 10. 6 months (95% CI, 187. 6,229. 1 ). The Kaplan-Meier survival analysis were performed for the survive time, examined with the covariates of age at onset of symptoms, age at diagnosis, sex, inheritance ( new mutation or inherited case), presence each type of NF2 lesions ( intracranial meningiomas, spinal tumors, peripheral neuropathy and ocular disorders). Results Group of aged at onset of symptoms groups 〉 19 years was significantly higher survival rate than group of aged ~〈 19 years ( P = 0. 006) ; Patients without spinal tumors had significantly higher survival rate than patients with spinal tumors ( P = 0. 009 ). Cox proportional hazards regression analysis indicated that presence with spinal tumors was the influencing factors for prognosis of NF2 patients. Conclusions NF2 is a clinically hetereogeneous disease with different phenotypes, presence with spinal tumors was associated with poor survival.
出处 《中华神经外科杂志》 CSCD 北大核心 2013年第10期980-983,共4页 Chinese Journal of Neurosurgery
基金 国家科技支撑计划课题(2012BAll2803) 国家自然科学基金(81372715) 首都卫生发展科研专项项目(首发2011-1015-01)
关键词 2型神经纤维瘤病 临床特征 预后 Neurofibromatosis type 2 Clinical characteristics Prognosis
  • 相关文献

参考文献17

  • 1Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet, 2009, 373:1974-1986.
  • 2Evans DG, Moran A, King A, et al . Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10- year period: higher incidence than previously thought. Otol Neurotol, 2005, 26: 93-97.
  • 3Merker VL, Esparza S, Smith MJ, et al. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist ,2012,17 : 1317-1322.
  • 4Baser ME, Friedman JM, Aesehliman D, et al. Predictors of the risk of mortality in neurofibromatos is 2. Am J Hum Genet, 2002, 71: 715-723.
  • 5Matsuo M, Ohno K, Ohtsuka F. Characterization of early onset neurofibromatosis type 2. Brain Dev, 2013. pii: S0387-7604 ( 13 )00025-9.
  • 6Aboukais R, Baroncini M, Zairi F, et al. Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. Acta Neurochirurgica,2013,155 : 771-777.
  • 7Fisher LM, Doherty JK, Lev MH, et al. Concordance of bilateral vestibular schwannoma growth and heating changes in neurofibromatosis 2 : neurofibromatosis 2 natural history consortium. Otol Neurotol,2009, 30:835-841.
  • 8Masuda A, Fisher LM, Oppenheimer ML, et al. Hearing cha- nges after diagnosis in neumfibmmatosis type 2. Otol Neurotol, 2004, 25: 150-154.
  • 9Samii M,Gerganov V, Samii A. Microsurgery management of ve- stibular schwannomas in neurofibromatosis type 2 : indications and results. Prog Neurol Surg, 2008, 21: 169-175.
  • 10Dirks MS, Butman JA, Kim HI, et al. Long-term natural history of neurofibromatosis type 2-associated intraeranial tumors. J Neurosurg, 2012,117 : 109 -117.

二级参考文献41

  • 1罗世祺,石祥恩.双侧听神经瘤[J].中华神经外科杂志,1995,11(5):267-269. 被引量:10
  • 2廖慧娟,廖二元,蒋波,魏启幼.2型神经纤维瘤病NF2基因的突变分析[J].中国临床医学,2005,12(4):585-587. 被引量:2
  • 3卞留贯,孙青芳,沈建康,罗其中.多发神经纤维瘤病的临床和分子生物学研究[J].中华神经外科疾病研究杂志,2005,4(5):477-479. 被引量:10
  • 4贺子建,王晓强,卞留贯,孙青芳.NF2基因及其蛋白merlin的生物学研究进展[J].国际神经病学神经外科学杂志,2006,33(2):194-197. 被引量:4
  • 5Ferner RE. Neurofi bromatosis 1 and neurofibromatosis 2 : a twenty first century perspective. Lancet Neurol, 2007, 6 : 340-351.
  • 6Baser ME, Friedman JM, Wallace A J, et al. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology, 2002, 59 : 1759-1765.
  • 7Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 ( NF2 ) : clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet, 1994, 52 : 450- 461.
  • 8Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med, 1992, 84: 603-618.
  • 9Sener RN, Dzelzite S, Migals A, et al. Prominent myelin vacuolization in neurofibromatosis type 2. Clin Imaging, 2003, 27 : 11-13.
  • 10Samii M, Gerganov V,Samii A. Microsurgery management of vestibular schwannomas in neurofibromatosis type 2: indications and results. Prog Neurnl Surg, 2008,21:169-175.

共引文献12

同被引文献66

  • 1曹学成.大鼠坐骨神经的解剖学研究[J].中国实验动物学杂志,2002,12(4):213-214. 被引量:19
  • 2王银改.ImageJ软件在检验医学图像分析处理中的应用[J].中华检验医学杂志,2005,28(7):747-748. 被引量:23
  • 3卞留贯,孙青芳,沈建康,罗其中.多发神经纤维瘤病的临床和分子生物学研究[J].中华神经外科疾病研究杂志,2005,4(5):477-479. 被引量:10
  • 4田峥巍,刘明辉.75例椎管内神经鞘瘤的手术治疗[J].中国肿瘤临床,2006,33(6):346-348. 被引量:2
  • 5李健,李学真,刘磊,杨宝,刘藏,杨俊,王贵怀.椎管内神经鞘瘤的显微外科治疗——附342例临床总结[J].中国神经肿瘤杂志,2007,5(1):17-21. 被引量:8
  • 6Makino S, Tampo H, Arai Y, e! al. Correlations between ehoroi- dal abnommlities, Liseh nodules, and age in patients with neurofi- bromatosis type 1. Clinical Ophthalmolo, (Auckland, NZ), 2014, 8:165.
  • 7Rouleau GA, Merel P, Lutchman M, et al. Aheration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 [ J ]. Nature, 1993,363 ( 6429 ) : 515- 521. DOI:10. 1038/363515a0.
  • 8Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought [ J ]. Otol Neuroto1,2005,26 ( 1 ) :93-97.
  • 9Ahronowitz I, Xin W, Kiely R, et al. Mutational spectrum of the NF2 gene:a meta-analysis of 12 years of research and diagnostic laboratory findings [ J]. Hum Mutat ,2007,28 ( 1 ) : 1-12.
  • 10Clark VE~ Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1 ,and SMO [ J ]. Science, 2013,339 ( 6123 ) : 1077-1080. DOI : 10.1126/science. 1233009.

引证文献11

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部